Literature DB >> 27931593

Techniques and Outcomes of Percutaneous Aortic Paravalvular Leak Closure.

Mohamad Alkhouli1, Mohammad Sarraf1, Elad Maor1, Saurabh Sanon1, Allison Cabalka1, Mackram F Eleid1, Donald J Hagler1, Peter Pollak1, Guy Reeder1, Charanjit S Rihal2.   

Abstract

OBJECTIVES: The aim of this study is to provide a summary of the currently applied aortic paravalvular leak (PVL) closure techniques and describe the procedural and long-term outcomes in a large consecutive cohort of patients.
BACKGROUND: Percutaneous repair has emerged as an effective therapy for patients with PVL. To date, clinical outcome data on percutaneous closure of aortic PVL are limited.
METHODS: All patients who underwent catheter-based treatment of aortic PVL between 2006 and 2015 were identified. Procedural and short-term results were assessed. Patients were contacted for clinical events and symptoms.
RESULTS: Eighty-six procedures were performed in 80 patients. The mean age was 68 ± 15 years, and 70% were men. The primary indications for PVL closure were symptoms of heart failure, hemolysis, and both in 83%, 5%, and 12%, respectively. Successful device deployment was accomplished in 94 defects (90%). Reduction in PVL to mild or less was achieved in 62% of patients. In-hospital major adverse events occurred in 8% of procedures. Symptomatic improvement at 30 days was achieved in 64% of patients. Patients who had reduction in the PVL grade to mild or less experienced more improvement in New York Heart Association functional class (from 2.93 ± 0.62 to 1.72 ± 0.73) compared with those with mild or greater residual leak (from 3.03 ± 0.57 to 2.52 ± 0.74) (p < 0.001). In patients with severe hemolysis (n = 8), transfusion requirements were eliminated in 7 (88%) after PVL closure. Kaplan-Meier survival analysis showed that the cumulative probability of freedom from repeat surgery at 2 years was 98 ± 2% in patients who had mild or less residual leak compared with 68 ± 10% in patients with higher grades of residual PVL (log-rank p = 0.004).
CONCLUSIONS: Percutaneous reduction of aortic PVL is associated with durable symptom relief and lower rates of repeat cardiac surgery. The magnitude of benefit is greatest with PVL reduction to a grade of mild or less. Therefore, attempts should be made to reduce PVL as much as possible. Copyright Â
© 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aortic regurgitation; paravalvular leak; percutaneous repair

Mesh:

Year:  2016        PMID: 27931593     DOI: 10.1016/j.jcin.2016.08.038

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  5 in total

1.  Transcatheter mitral valve replacement: an evolution of a revolution.

Authors:  Mohamad Alkhouli; Fahad Alqahtani; Sami Aljohani
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 2.  Paravalvular Leak in Structural Heart Disease.

Authors:  Kashish Goel; Mackram F Eleid
Journal:  Curr Cardiol Rep       Date:  2018-03-06       Impact factor: 2.931

3.  Intracardiac versus transesophageal echocardiography to guide transcatheter closure of interatrial communications: Nationwide trend and comparative analysis.

Authors:  Fahad Alqahtani; Ashwin Bhirud; Sami Aljohani; James Mills; Akram Kawsara; Ashok Runkana; Mohamad Alkhouli
Journal:  J Interv Cardiol       Date:  2017-04-25       Impact factor: 2.279

Review 4.  Cardiac prostheses-related hemolytic anemia.

Authors:  Mohamad Alkhouli; Ali Farooq; Ronald S Go; Sudarshan Balla; Chalak Berzingi
Journal:  Clin Cardiol       Date:  2019-05-06       Impact factor: 2.882

5.  Safety, Efficacy and Long-Term Outcomes of Patients Treated with the Occlutech Paravalvular Leak Device for Significant Paravalvular Regurgitation.

Authors:  Eustaquio Maria Onorato; Francesco Alamanni; Manuela Muratori; Grzegorz Smolka; Wojtek Wojakowski; Piotr Pysz; Aleksejus Zorinas; Diana Zakarkaite; Hélène Eltchaninoff; Pierre-Yves Litzer; François Godart; Patrick Calvert; Christos Christou; Abdurashid Mussayev; Bindo Missiroli; Igor Buzaev; Salvatore Curello; Tullio Tesorio; Antonio Luca Bartorelli
Journal:  J Clin Med       Date:  2022-04-01       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.